Skip to main content
SpringerLink
Log in

Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic Dose

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Low-molecular weight heparins (LMWHs) have been shown to be as safe and effective as unfractionated heparin (UFH) for the treatment of acute venous thrombosis and non-life-threatening pulmonary embolism. Different reports have shown that LMWHs may also be used to treat patients with unstable angina or non-Q-wave infarction. The safety of LMWHs used at therapeutic dose has been widely studied in pivotal clinical trials and analysed in several meta-analyses. However, despite the wide development and use of LMWHs, several issues regarding the safety and optimal use of LMWHs remain unanswered.

The main adverse effect of LMWHs is bleeding and it is uncertain whether a weight-adjusted dosage regimen without laboratory monitoring can be used in patients with a high risk of bleeding, such as patients with renal failure, elderly patients, obese patients or pregnant women. These patients are usually excluded from clinical trials and only a few studies, not sufficiently powered to estimate efficacy and safety, have been carried out in these special populations. Most of the available data comes from pharmacokinetic or population pharmacodynamic studies or clinical reports. Results in patients with renal impairment who are not undergoing haemodialysis suggest that a reduction in calculated creatinine clearance levels is associated with an increased risk of accumulation of anti-Xa activity, the extent of which differs depending on the individual LMWH and the extent to which the compound is cleared by the kidney. The limited data available regarding the use of therapeutic doses of LMWHs in obese patients suggest that there is no need to cap the dose at a maximal allowable dose. Long-term (3-month) treatment with LMWHs appears to be as effective and safe as oral anticoagulant therapy for the treatment of venous thromboembolism. It appears that each LMWH is a distinct compound with unique pharmacokinetic and pharmacodynamic profiles. Until more data are available regarding these special populations, periodic monitoring of anti-Xa activity levels may be recommended to detect accumulation and/or an overdose and minimise the bleeding risk.

The non-haemorrhagic adverse effects of the LMWHs include heparin-induced thrombocytopenia (HIT) and osteoporosis. The incidence of HIT appears to be lower with LMWHs than with UFH; there is currently not enough data to compare the frequency of HIT between the various LMWHs. LMWHs also appear to carry a lower risk of causing osteoporosis than UFH.

In conclusion, studies that include special population patients are required to make conclusive recommendations concerning the safety and monitoring of the different LMWHs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Hirsh J, Anand SS, Halperin JL, et al. AHA Scientific statement: guide to anticoagulant therapy. Heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103: 2994–3018

    Article  PubMed  CAS  Google Scholar 

  2. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355(9219): 1936–42

    Article  PubMed  CAS  Google Scholar 

  3. Samama MM, Desnoyers P, Gerotziafas GT. Low molecular weight heparins: a comparative review of pharmacodynamic, clinical pharmacology. In: Lugassy G, Brenner B, Schulman S, Samama MM, Cohen M, editors. Thrombosis and antithrombotic therapy. London: Martin Dunitz, 2001: 71–96

    Google Scholar 

  4. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigator. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997; 29 (7): 1474–82

    Google Scholar 

  5. Bratt G, Tornebohm E, Granqvist S, et al. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985; 54(4): 813–7

    PubMed  CAS  Google Scholar 

  6. Leizorovicz A, Simonneau G, Decousus H, et al. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309(6950): 299–304

    Article  PubMed  CAS  Google Scholar 

  7. Lensing AW, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995; 155(6): 601–7

    Article  PubMed  CAS  Google Scholar 

  8. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs 1996; 52Suppl. 7: 30–7

    Article  PubMed  CAS  Google Scholar 

  9. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100(3): 230–769-77

    Article  Google Scholar 

  10. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130(10): 800–9

    PubMed  CAS  Google Scholar 

  11. Rocha E, Martinez-Gonzalez MA, Montes R, et al. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica 2000; 85(9): 935–42

    PubMed  CAS  Google Scholar 

  12. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160(2): 181–8

    Article  PubMed  CAS  Google Scholar 

  13. van Den Belt AG, Prins MH, Lensing AW, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2000; (2): CD001100

  14. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140(3): 175–83

    PubMed  CAS  Google Scholar 

  15. Riess H, Koppenhagen K, Tolle A, et al. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thromb Haemost 2003; 90(2): 252–9

    PubMed  CAS  Google Scholar 

  16. Planes A. Review of bemiparin sodium: a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin Pharmacother 2003; 4(9): 1551–61

    PubMed  CAS  Google Scholar 

  17. van Dongen CJ, Mac Gillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2003; (1): CD003074

  18. Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Thromb Haemost 2001; 86(4): 980–4

    PubMed  CAS  Google Scholar 

  19. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Fragmin and fast revascularisation during instability in coronary artery disease investigators. Lancet 1999; 354 (9180): 708–15

  20. Fragmin during instability in coronary artery disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347 (9001): 561–8

    Google Scholar 

  21. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96(1): 61–8

    Article  PubMed  CAS  Google Scholar 

  22. The FRAXIS study group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX I.S. (Fraxiparine in ischaemic syndrome). Eur Heart J 1999; 20 (21): 1553–62

    Google Scholar 

  23. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997; 337(7): 447–52

    Article  PubMed  CAS  Google Scholar 

  24. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100(15): 1593–601

    Article  PubMed  CAS  Google Scholar 

  25. Husted S, Becker R, Kher A. A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease. Clin Cardiol 2001; 24(7): 492–9

    Article  PubMed  CAS  Google Scholar 

  26. Michalis LK, Katsouras CS, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003; 146(2): 304–10

    Article  PubMed  CAS  Google Scholar 

  27. Cestac P, Bagheri H, Lapeyre-Mestre M, et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf 2003; 26(3): 197–207

    Article  PubMed  CAS  Google Scholar 

  28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41

    Article  PubMed  CAS  Google Scholar 

  29. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162(22): 2605–9

    Article  PubMed  Google Scholar 

  30. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63(3): 385–90

    Article  PubMed  CAS  Google Scholar 

  31. Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20(7): 771–5

    Article  PubMed  CAS  Google Scholar 

  32. Brophy DF, Wazny LD, Gehr TW, et al. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy 2001; 21(2): 169–74

    Article  PubMed  CAS  Google Scholar 

  33. Collet JP, Montalescot G, Choussat R, et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001: 80(1): 81–2

    Article  PubMed  CAS  Google Scholar 

  34. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105(3): 225–31

    Article  PubMed  CAS  Google Scholar 

  35. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143(5): 753–9

    Article  PubMed  CAS  Google Scholar 

  36. Bruno R, Baille P, Retout S, et al. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 2003; 56(4): 407–14

    Article  PubMed  CAS  Google Scholar 

  37. Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43(6): 586–90

    PubMed  CAS  Google Scholar 

  38. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146(1): 33–41

    Article  PubMed  CAS  Google Scholar 

  39. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41(1): 8–14

    Article  PubMed  CAS  Google Scholar 

  40. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110(4): 392–8

    Article  PubMed  CAS  Google Scholar 

  41. Hulot JS, Vantelon C, Urien S, et al. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit 2004; 26(3): 305–10

    Article  PubMed  CAS  Google Scholar 

  42. Goudable C, Saivin S, Houin G, et al. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 1991; 59(4): 543–5

    Article  PubMed  CAS  Google Scholar 

  43. Baumelou A, Singlas E, Petitclerc T, et al. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. Nephron 1994; 68(2): 202–6

    Article  PubMed  CAS  Google Scholar 

  44. Hainer JW, Sherrard DJ, Swan SK, et al. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 2002; 40(3): 531–8

    Article  PubMed  CAS  Google Scholar 

  45. Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002; 40(5): 990–5

    Article  PubMed  CAS  Google Scholar 

  46. Swedko PJ, Clark HD, Paramsothy K, et al. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003; 163(3): 356–60

    Article  PubMed  CAS  Google Scholar 

  47. Goldberg TH, Finkelstein MS. Difficulties in estimating glomerular filtration rate in the elderly. Arch Intern Med 1987; 147(8): 1430–3

    Article  PubMed  CAS  Google Scholar 

  48. Bliss MR, Vellupillai S, Julian PA, et al. Measured and predicted creatinine clearance [letter]. Lancet 1987; I(8536): 815

    Article  Google Scholar 

  49. Siguret V, Pautas E, Gouin I. Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004. Curr Opin Pulm Med 2004; 10(5): 366–70

    Article  PubMed  CAS  Google Scholar 

  50. Merli GJ. Treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin in the geriatric patient population. Clin Geriatr Med 2001; 17(1): 93–106

    Article  PubMed  CAS  Google Scholar 

  51. Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998; 79(6): 1162–5

    PubMed  CAS  Google Scholar 

  52. Siguret V, Pautas E, Fevrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84(5): 800–4

    PubMed  CAS  Google Scholar 

  53. Pautas E, Gouin I, Bellot O, et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002; 25(10): 725–33

    Article  PubMed  CAS  Google Scholar 

  54. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72(3): 308–18

    Article  PubMed  CAS  Google Scholar 

  55. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavyweight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002; 87(5): 817–23

    PubMed  CAS  Google Scholar 

  56. Wilson SJ, Wilbur K, Burton E, et al. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001; 31(1): 42–8

    PubMed  CAS  Google Scholar 

  57. Smith J, Canton EM. Weight-based administration of dalteparin in obese patients. Am J Health Syst Pharm 2003; 60(7): 683–7

    PubMed  CAS  Google Scholar 

  58. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost 2003; 1(7): 1435–42

    Article  PubMed  CAS  Google Scholar 

  59. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126Suppl. (3 Suppl.): 627S–44S

    Article  PubMed  CAS  Google Scholar 

  60. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81(1): 26–31

    PubMed  CAS  Google Scholar 

  61. Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20(5): 521–6

    Article  PubMed  CAS  Google Scholar 

  62. Veiga F, Escriba A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000; 84(4): 559–64

    PubMed  CAS  Google Scholar 

  63. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72(2): 191–7

    PubMed  CAS  Google Scholar 

  64. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71(1): 7–11

    PubMed  CAS  Google Scholar 

  65. Monreal M, Roncales FJ, Ruiz J. Secondary prevention of venous thromboembolism: a role for low-molecular-weight heparin. Haemostasis 1998; 28: 236–43

    PubMed  CAS  Google Scholar 

  66. Hull RD, Pineo GF, Mah AF. Home-Lite: safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal venous thrombosis using subcutaneous low-molecular-weight heparin versus warfarin [abstract OC1647]. Thromb Haemost 2001 Jul

    Google Scholar 

  67. Hull RD, Pineo GF, Mah AF. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract OC395]. J Thromb Haemost 2003 Jul

    Google Scholar 

  68. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003; 1(9): 1906–13

    Article  PubMed  CAS  Google Scholar 

  69. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(1 Suppl.): 64S–94S

    Article  PubMed  CAS  Google Scholar 

  70. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl.): 188S–203S

    Article  PubMed  CAS  Google Scholar 

  71. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2(4): 551–4

    Article  PubMed  CAS  Google Scholar 

  72. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, et al. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 1994; 71(6): 698–702

    PubMed  CAS  Google Scholar 

  73. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 2001; 27(5): 519–22

    Article  PubMed  CAS  Google Scholar 

  74. Hirsh J. Laboratory monitoring of low-molecular-weight heparin therapy. J Thromb Haemost 2004; 2(6): 1003

    Article  PubMed  CAS  Google Scholar 

  75. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 21(2): 218–34

    Article  PubMed  CAS  Google Scholar 

  76. Boneu B, Nguyen F, Cambus J. Difficulties and pitfalls in the monitoring of heparin therapy. Sang Thrombose Vaisseaux 2003; 15(3): 131–4

    Google Scholar 

  77. Harenberg J. Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis. Curr Opin Pulm Med 2002; 8(5): 383–8

    Article  PubMed  Google Scholar 

  78. Messmore H, Jeske W, Wehrmacher W, et al. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Drug Saf 2003; 26(9): 625–41

    Article  PubMed  CAS  Google Scholar 

  79. Lee D, Warkentin T. Frequency of heparin-induced thrombocytopenia. In: Warkentin T, Greinacher A, editors. Heparininduced thrombocytopenia. New York: Marcel Dekker, 2001: 87–122

    Google Scholar 

  80. Warkentin T. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin T, Greinacher A, editors. Heparininduced thrombocytopenia. New York: Marcel Dekker, 2001: 43–86

    Google Scholar 

  81. Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003; 121(5): 786–92

    Article  PubMed  CAS  Google Scholar 

  82. Breddin HK, Hach-Wunderle V, Nakov R, et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344(9): 626–31

    Article  PubMed  CAS  Google Scholar 

  83. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med 1997; 337(10): 663–9

    Article  PubMed  CAS  Google Scholar 

  84. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334(11): 682–7

    Article  PubMed  CAS  Google Scholar 

  85. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334(11): 677–81

    Article  PubMed  CAS  Google Scholar 

  86. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153(13): 1541–6

    Article  PubMed  CAS  Google Scholar 

  87. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326(15): 975–82

    Article  PubMed  CAS  Google Scholar 

  88. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76(2): 195–9

    PubMed  CAS  Google Scholar 

  89. Lindmarker P, Holmstrom M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72(2): 186–90

    PubMed  CAS  Google Scholar 

  90. Prandoni P, Vigo M, Cattelan AM, et al. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216). Haemostasis 1990; 20Suppl. 1: 220–3

    PubMed  Google Scholar 

  91. Pettila V, Leinonen P, Markkola A, et al. Postpartum bone marrow mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMWHeparin. Thromb Haemost 2002; 87: 182–6

    PubMed  CAS  Google Scholar 

  92. Hui CK, Yuen MF, OI-Lin Ng I, et al. Low molecular weight heparin-induced liver toxicity. J Clin Pharmacol 2001; 41(6): 691–4

    Article  PubMed  CAS  Google Scholar 

  93. Liautard C, Nunes AM, Vial T, et al. Low-molecular-weight heparins and thrombocytosis. Ann Pharmacother 2002; 36(9): 1351–4

    Article  PubMed  CAS  Google Scholar 

  94. Abdel-Raheem MM, Potti A, Tadros S, et al. Effect of low-molecular-weight heparin on potassium homeostasis. Pathophysiol Haemost Thromb 2002; 32(3): 107–10

    Article  PubMed  CAS  Google Scholar 

  95. Gheno G, Cinetto L, Savarino C, et al. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol 2003: 59: 373–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Dr M. Harboun for his help in the critical review of this article. No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Laboratoire d’Hématologie, Hôpital Charles Foix (University Hospital of Paris), 7 avenue de la République, 94205, Ivry sur Seine cedex, France

    Isabelle Gouin-Thibault & Virginie Siguret

  2. Médecine Interne, Gériatrie, Hôpital Charles Foix (University Hospital of Paris), Ivry/Seine, France

    Eric Pautas

Authors
  1. Isabelle Gouin-Thibault
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Pautas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Virginie Siguret
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isabelle Gouin-Thibault.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gouin-Thibault, I., Pautas, E. & Siguret, V. Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic Dose. Drug-Safety 28, 333–349 (2005). https://doi.org/10.2165/00002018-200528040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200528040-00005

Keywords

Search

Navigation